View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

AbbVie Inc.: Key facts and statistics - LTM June 2024

A summary company profile, detailing AbbVie Inc.’s business operations and financial highlights.

AbbVie Inc. - June 2024 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Abbvie Inc: 1 director

A director at Abbvie Inc sold 66,500 shares at 186.520USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

AbbVie Inc.: Update to credit analysis following outlook revision to p...

Our credit view of this issuer reflects its articulated target of 2x net debt / EBITDA, against its ongoing earnings erosion through 2024 due to US biosimilar competition for Humira.

Moody's Ratings affirms AbbVie's A3 ratings; revises outlook to positi...

Moody's Ratings (Moody's) affirmed the ratings of AbbVie Inc. ("AbbVie") including the A3 senior unsecured notes, A3 issuer rating and the Prime-2 senior unsecured commercial paper rating. At the same time, we revised AbbVie's outlook to positive from stable. The change in AbbVie's outlook to posi...

AbbVie Inc. - March 2024 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Research Team ACF
  • Research Team ACF

Regenerative Healthcare - Stem Cells & ALS Thematic 10062024

Regenerative medicine remains an extremely exciting area of healthcare with vast investment potential. In spite of the usual setbacks in valuation and strategy, the sub-sector has pivoted and the market remains innovative and attracts investment capital. Rather than replace entire tissues, which is a complex activity, we believe the immediate future for stem cells is more likely to be in the successful stimulation of the bodies on repair mechanisms. Within regenerative medicine we believe there ...

AbbVie Inc. - December 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

AbbVie Inc.: Update to credit analysis following ImmunoGen and Cerevel...

Our credit view of this issuer reflects its strong competitive position and solid cash flow tempered by execution risk related to the acquisitions of ImmunoGen and Cerevel.

AbbVie Inc. - September 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Moody's affirms AbbVie's A3 rating; stable outlook

Moody's Investors Service ("Moody's") affirmed the ratings of AbbVie Inc. ("AbbVie") including the A3 senior unsecured notes, issuer rating and the Prime-2 senior unsecured commercial paper ratings. The outlook is maintained at stable. These actions follow the announcement that AbbVie will acquire C...

Moody's: AbbVie's ImmunoGen acquisition enhances oncology franchise wi...

Moody's Investors Service commented that AbbVie Inc.'s announcement that it will acquire ImmunoGen, Inc. for approximately $10.1 billon will enhance its oncology franchise by adding the approved drug Elahere to AbbVie's portfolio. The acquisition also brings oncology pipeline opportunities including...

AbbVie Inc.: ImmunoGen acquisition enhances oncology franchise with on...

The acquisition provides a growing oncology drug with blockbuster potential and keeps debt/EBITDA within our expectations

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

AbbVie Inc.: Key facts and statistics - LTM June 2023

A summary company profile, detailing AbbVie Inc.’s business operations and financial highlights.

AbbVie Inc. - June 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

AbbVie Inc.: Update to credit analysis following upgrade to A3

Our credit view of this issuer reflects its large scale, immunology focus and solid cash flow, against Humira biosimilar exposure and event risk associated with debt-financed acquisitions.

Moody's upgrades AbbVie to A3; outlook stable

Moody's Investors Service (Moody's) upgraded the senior unsecured long-term ratings of AbbVie Inc. (AbbVie) to A3 from Baa1. At the same time, Moody's affirmed AbbVie's Prime-2 short-term commercial paper rating. Following these actions, the outlook is stable. "The rating upgrade results from ongo...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch